MSB

2.70%

95.0¢ mesoblast limited

Ann: Mesoblast Type A Meeting with FDA, page-70

First 70 Last

Share
Profile

Follow
rvajna

8,582 Posts.

623

21/09/23

14:35

Post #: 69959395
Share

Originally posted by bedger: ↑

Contrary to many of the posts above I believe there is actually some real inconsistency here. Krause very clearly said in the recent post CRL conference that the FDA did not question efficacy:

"one of the significant positive indicators from the CRL - is that the CRL did not question the efficacy of the product as demonstrated in GvHD001, (which was the case for the previous CRL )" (Krause, 31 Aug 2023)

But then in this update:

"FDA noted that the lack of a suitable potency assay for the RYONCIL product used during the Phase 3 trial MSB-GVHD001 for the pediatric acute GVHD indication has prevented the trial from being considered an adequate study for the purpose of demonstrating substantial evidence of effectiveness required for a marketing approval."

If they didn't accept the potency assay, then they didn't in fact accept the efficacy as demonstrated by GVHD0001.

Perhaps I am wrong, but I think Silviu and Krause, are loudly here setting out the inconsistencies they are dealing with from the FDA themselves, for all too see, and showing all how they are arguing with the FDA on the validity of the potency assay and adding ever more data to back their claim and refute the contentions of the FDA, which they are showing as inconsistent and are picking away at.

"FDA indicated its willingness to consider Mesoblast’s proposed registrational trial design in adults, subject to agreement on the suitability of the potency assay for the product to be used in adults."

Clearly they are making some difficult progress on the potency assays with the FDA, both past used and those going forward and can't jeopardize that too much by too loudly pointing out FDA inconsistency, which has been shown innumerable times in other treatment decisions/processing by the FDA.

(happy be corrected by more informed MSB posters - not the peanut brigade)

Expand

Picked up another parcel at 37.5 cents. It has to be of value at some point.

MSB Price at posting: 37.5¢ Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Bitcoin: Current State of Play & Where to Next | Swyftx

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

HZR

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

NEU

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Revolutionary inverter technology leads the clean energy charge

Emerald & Azure score Digger & Dealer awards

TNC

True North increases silver metal at QLD's Vero deposit by 20%

TKM

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

There are more pages in this discussion • 505 more messages in this thread...

First 70 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 95.0¢		Change 0.025(2.70%)		Mkt cap ! $1.084B

Open	High	Low	Value	Volume
94.0¢	96.8¢	93.5¢	$4.207M	4.417M

Buyers (Bids)

No.	Vol.	Price($)
3	42268	94.0¢

Sellers (Offers)

Price($)	Vol.	No.
95.0¢	48002	3

View Market Depth

No.	Vol.	Price($)
2	41000	0.940
4	39720	0.935
1	20000	0.930
6	60000	0.925
2	431086	0.920

Price($)	Vol.	No.
0.950	30347	2
0.955	20000	1
0.960	47000	2
0.965	35223	3
0.970	259286	4

Last trade - 16.10pm 09/08/2024 (20 minute delay)

MSB (ASX) Chart

Ann: Mesoblast Type A Meeting with FDA, page-70

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Bitcoin: Current State of Play & Where to Next | Swyftx

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Revolutionary inverter technology leads the clean energy charge

Emerald & Azure score Digger & Dealer awards

True North increases silver metal at QLD's Vero deposit by 20%

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Mesoblast Type A Meeting with FDA, page-70

Top Stories

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Bitcoin: Current State of Play & Where to Next | Swyftx

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Revolutionary inverter technology leads the clean energy charge

Emerald & Azure score Digger & Dealer awards

True North increases silver metal at QLD's Vero deposit by 20%

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News